Tag: small molecule

Shanghai (China) base CStone Pharmaceuticals has submitted a Phase 1b clinical trial application in Australia for CS5001, a receptor tyrosine kinase-like orphan receptor 1 (ROR1-) targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for the treatment of Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL).